Search Results for "moderate concentrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for moderate concentrate. Results 261 to 270 of 505 total matches.

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
serum concentrations; INR changes in patients taking warfarin and rifaximin Bile Acid Sequestrants ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721f |  Show IntroductionHide Introduction

Methamphetamine Abuse

   
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004  (Issue 1188)
are postponed, and sustained mental concentration becomes difficult and may be replaced by a rapid flight ...
Methamphetamine, a highly addictive synthetic sympathomimetic, has again become important as a drug of abuse in the US. Its resurgence has been associated with unsafe sexual practices that have resulted in an increase in HIV transmission, particularly among men who have sex with men (SJ Semple et al, J Subst Abuse Treat 2002; 22:149; A Urbina and K Jones, Clin Infect Dis 2004; 38:890).
Med Lett Drugs Ther. 2004 Aug 2;46(1188):62-3 |  Show IntroductionHide Introduction

Perampanel (Fycompa) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
) that significantly lowered serum concentrations of perampanel.3-5 A pooled analysis of all 3 studies found ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):9-10 |  Show IntroductionHide Introduction

Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
SKs. MECHANISM OF ACTION — Eskata is a highly concentrated (40% w/w) solution of stabilized hydrogen ...
The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication. (Hydrogen peroxide is available over the counter for topical use as a 3% solution.)
Med Lett Drugs Ther. 2018 Sep 24;60(1556):157-8 |  Show IntroductionHide Introduction

Trofinetide (Daybue) for Rett Syndrome (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
structure, normalizes synthesis of essential proteins, reduces apoptosis, augments concentrations ...
Trofinetide (Daybue – Acadia), a synthetic analog of glycine-proline-glutamate, has been approved by the FDA for treatment of Rett syndrome in patients ≥2 years old. It is the first drug to be approved in the US for treatment of Rett syndrome.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e115-6   doi:10.58347/tml.2024.1706d |  Show IntroductionHide Introduction

Once-Daily Mesalamine (Lialda) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007  (Issue 1257)
with mild to moderate ulcerative colitis. MECHANISM OF ACTION — Mesalamine (5-ASA) acts locally against ...
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Med Lett Drugs Ther. 2007 Mar 26;49(1257):25-6 |  Show IntroductionHide Introduction

Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
, plasma concentrations of dexmedetomidine were generally quantifiable 5-20 minutes aftertaking Igalmi ...
The FDA has approved a sublingual film formulation of the alpha-2 adrenergic receptor agonist dexmedetomidine (Igalmi — BioXcel Therapeutics) for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It is the first alpha-2 agonist and the only sublingual film to be approved for this indication. Dexmedetomidine has been available for many years in an injectable formulation (Precedex) for sedation in the intensive care unit and to facilitate procedures such as mechanical ventilation.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):203-5 |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
effective in two 28-day clinical trials in patients with mild to moderate atopic dermatitis ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005  (Issue 1218)
, has been approved by the FDA for single-dose treatment of mild to moderate community-acquired pneumonia (CAP ...

Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.

Med Lett Drugs Ther. 2005 Sep 28;47(1218):78-80 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
concentrations fall after the first few weeks of treatment Risk of developmental toxicity unclear; studies ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction